BI 1291583
Alternative Names: BI-1291583Latest Information Update: 02 Jun 2025
At a glance
- Originator Boehringer Ingelheim
- Class Antibronchitics
- Mechanism of Action Dipeptidyl peptidase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bronchiectasis
Most Recent Events
- 29 Apr 2025 Boehringer Ingelheim initiates enrollment in a phase I drug-drug interaction trial(In volunteers) in Germany (PO) (NCT06917872)(EudraCT2024-515795-12-00)
- 09 Apr 2025 Boehringer Ingelheim plans a phase I drug-drug interaction trial in Germany (PO) in April 2025 (NCT06917872)
- 28 Mar 2025 No recent reports of development identified for phase-I development in Bronchiectasis(In volunteers, In adults) in Japan (PO, Tablet)